Rexahn Pharmaceuticals (RNN) 0.72 $RNN
Rexahn Pharmaceuticals Provides Update on Phase I Supinoxin Trial in Cancer Patients with Solid Tumors
Business Wire - Fri Jul 18, 8:00AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced an update in its Phase I multi-center dose-escalation study to evaluate the safety, tolerability, dose-limiting toxicities and maximum tolerated dose (MTD) of Supinoxin(TM) (RX-5902) in cancer patients with solid tumors.
Stock to Watch: Rexahn Pharmaceuticals Down 5.2% (RNN)
Comtex SmarTrend(R) - Tue Jul 15, 10:38AM CDT
Rexahn Pharmaceuticals (AMEX:RNN) is one of today's worst performing penny stocks, down 5.2% to $0.76 on 1.1x average daily volume. Thus far today, Rexahn Pharmaceuticals has traded 1.4 million shares, vs. average volume of 1.3 million shares per day. The stock has underperformed the Dow (-5.1% to the Dow's -0.0%) and underperformed the S&P 500 (-5.1% to the S&P's -0.2%) during today's trading.
What Falling Estimates & Price Mean for Rexahn Pharmaceuticals (RNN) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 16, 7:45AM CDT
Rexahn Pharmaceuticals one such stock considered to drop as it has witnessed a significant price decline and has also seen negative earnings.
Stock to Watch: Rexahn Pharmaceuticals Up 7.7% (RNN)
Comtex SmarTrend(R) - Thu Jun 12, 10:41AM CDT
Rexahn Pharmaceuticals (AMEX:RNN) is one of today's best performing low-priced stocks, up 7.7% to $1.01 on 1.1x average daily volume. Thus far today, Rexahn Pharmaceuticals has traded 2.7 million shares, vs. average volume of 2.6 million shares per day. The stock has outperformed the Dow (8.3% to the Dow's -0.3%) and outperformed the S&P 500 (8.3% to the S&P's -0.3%) during today's trading.
Stocks Coverage on Biotech Equities -- Research on Gilead Sciences, ARIAD Pharma, Rexahn Pharma, and Geron
PR Newswire - Fri May 30, 6:10AM CDT
On Thursday, May 29, 2014, the NASDAQ Composite ended at 4,247.95, up 0.54%, the Dow Jones Industrial Average finished the day 0.39% higher at 16,698.74, and the S&P 500 closed at 1,920.03, up 0.54%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 688.45, up 0.76%, and the index has advanced 2.45% in the last one month. Investor-Edge has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN) and Geron Corp. (NASDAQ: GERN). Free technical research on GILD, ARIA, RNN and GERN can be downloaded upon signing up at:
Three biotechs stocks with positive institutional transactions, good price to cash ratios and "buy" recommendations from street analysts
ACCESSWIRE - Thu May 22, 7:09AM CDT
LOS ANGELES / ACCESSWIRE / May 22, 2014 / The names of big-board biotechnology listed firms IsoRay, Inc. (NYSE MKT: ISR), CEL-SCI Corporation (NYSE MKT: CVM), and Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), came up after we set out to find low price biotech stocks with market caps in the $50m to $300m range which, based on a fixed set of fundamental and technical criteria, might be hinting at bullish investment trade sentiments.
Rexahn Pharmaceuticals to Present Data on RX-3117 and RX-21101 at the 2014 American Association for Clinical Research Annual Meeting
Business Wire - Wed Apr 02, 8:00AM CDT
--RX-21101, a nano-polymer targeted form of docetaxel, demonstrates increased efficacy and reduced toxicity
Active Equities Updates -- Research on Valero Energy, UTi Worldwide, SLM Corp., and Rexahn Pharma
PR Newswire - Tue Apr 01, 8:00AM CDT
The trading session on Monday, March 31, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,457.66, up 0.82% and the NASDAQ Composite closed at 4,198.99, up 1.04%. The S&P 500 finished the session 0.79% higher at 1,872.34. The gains were broad based as nine out of ten sectors finished higher. During the session, gains in the Health Care, Materials, and Utilities sectors positively impacted the broader market. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include Valero Energy Corp. (NYSE: VLO), UTi Worldwide Inc. (NASDAQ: UTIW), SLM Corp. (NASDAQ: SLM) and Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN). Free technical research on VLO, UTIW, SLM and RNN can be downloaded upon signing up at:
Rexahn Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results and Recent Highlights
Business Wire - Mon Mar 24, 7:00AM CDT
--Archexin(R) Phase IIa clinical trial initiated in metastatic renal cell carcinoma
3 Stocks Under $10 Making Big Moves
at The Street - Wed Mar 19, 5:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Rexahn Pharmaceuticals to Present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum in New York
Business Wire - Mon Mar 17, 7:00AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Vikas Sharma, Ph.D., the Company's Director, Business Development, will present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum in New York on Wednesday, March 19, 2014. Dr. Sharma will also serve on an expert panel titled "Strategies for small molecules and biologicals drug development." The conference will take place at New York Academy of Sciences, located at 250 Greenwich St, New York, NY.
This Week in Biotech: NW Bio Soars While Geron Goes Geronimo
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 15, 2:15PM CDT
With the SPDR S&P Biotech Index up 59% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Phase I Data on Rexahn's Supinoxin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 4:30PM CDT
Initial data from phase I study on Rexahn's Supinoxin showed that the drug was well tolerated in cancer patients with solid tumors.
Why Rexahn Pharmaceuticals Inc. Jumped Higher
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 11, 1:58PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Rexahn Pharmaceuticals , a clinical-stage...
Rexahn Pharmaceuticals Up 11.1%, Shares Break Through Resistance (RNN)
Comtex SmarTrend(R) - Tue Mar 11, 11:41AM CDT
Rexahn Pharmaceuticals (AMEX:RNN) is one of today's best performing low-priced stocks, up 11.1% to $1.38 on 1.0x average daily volume. Thus far today, Rexahn Pharmaceuticals has traded 11.0 million shares, vs. average volume of 10.6 million shares per day. The stock has outperformed the Dow (10.7% to the Dow's -0.3%) and outperformed the S&P 500 (10.7% to the S&P's -0.3%) during today's trading.
Investor-Edge.com Pre-market Biotech Picks: Rexahn Pharma, Amgen, Galena Biopharma, and MannKind
PR Newswire - Tue Mar 11, 10:32AM CDT
On Monday, March 10, 2014, the NASDAQ Composite ended at 4,334.45, down 0.04%, the Dow Jones Industrial Average fell 0.21% to 16,418.68, and the S&P 500 closed at 1,877.17, down 0.05%. The losses were broad based as six out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 689.78, up 0.39%, and has gained 4.92% in the last one month. Investor-Edge.com has initiated coverage on the following equities: Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN), Amgen Inc. (NASDAQ: AMGN), Galena Biopharma Inc. (NASDAQ: GALE), and MannKind Corporation (NASDAQ: MNKD). Free research on these four companies can be accessed at:
Rexahn Announces Initial Results from Phase I Trial of Supinoxin(TM) (RX-5902) for Solid Cancer Tumors
Business Wire - Tue Mar 11, 7:00AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company announced today initial data for the Phase I dose-escalation clinical trial of Supinoxin(TM) (RX-5902) initiated in August 2013. This trial was designed to study safety and efficacy in patients with solid cancer tumors.
Biotech Stock Mailbag: Exact Sciences, Rexahn, Advaxis, Peregrine
at The Street - Fri Mar 07, 9:49AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Rexahn Pharmaceuticals to Present at the 26th Annual ROTH Conference
Business Wire - Tue Mar 04, 7:00AM CST
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Peter Suzdak, PhD, the Company's Chief Executive Officer and Ted Jeong, Chief Financial Officer, will present at the 26th Annual ROTH Conference on Tuesday, March 11, 2014 at 2:00 p.m. Pacific Time. The conference takes place at The Ritz-Carlton in Dana Point, California. A webcast of the presentation will be available on www.rexahn.com.
Rexahn Pharmaceuticals Appoints Mark Carthy to Board of Directors
Business Wire - Mon Mar 03, 7:00AM CST
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company, announced today the appointment of Mark P. Carthy to the company's Board of Directors.
Rexahn Pharmaceuticals Provides Update on Phase I Supinoxin Trial in Cancer Patients with Solid Tumors
Business Wire - Fri Jul 18, 8:00AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced an update in its Phase I multi-center dose-escalation study to evaluate the safety, tolerability, dose-limiting toxicities and maximum tolerated dose (MTD) of Supinoxin(TM) (RX-5902) in cancer patients with solid tumors.
Stock to Watch: Rexahn Pharmaceuticals Down 5.2% (RNN)
Comtex SmarTrend(R) - Tue Jul 15, 10:38AM CDT
Rexahn Pharmaceuticals (AMEX:RNN) is one of today's worst performing penny stocks, down 5.2% to $0.76 on 1.1x average daily volume. Thus far today, Rexahn Pharmaceuticals has traded 1.4 million shares, vs. average volume of 1.3 million shares per day. The stock has underperformed the Dow (-5.1% to the Dow's -0.0%) and underperformed the S&P 500 (-5.1% to the S&P's -0.2%) during today's trading.
What Falling Estimates & Price Mean for Rexahn Pharmaceuticals (RNN) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 16, 7:45AM CDT
Rexahn Pharmaceuticals one such stock considered to drop as it has witnessed a significant price decline and has also seen negative earnings.
Stock to Watch: Rexahn Pharmaceuticals Up 7.7% (RNN)
Comtex SmarTrend(R) - Thu Jun 12, 10:41AM CDT
Rexahn Pharmaceuticals (AMEX:RNN) is one of today's best performing low-priced stocks, up 7.7% to $1.01 on 1.1x average daily volume. Thus far today, Rexahn Pharmaceuticals has traded 2.7 million shares, vs. average volume of 2.6 million shares per day. The stock has outperformed the Dow (8.3% to the Dow's -0.3%) and outperformed the S&P 500 (8.3% to the S&P's -0.3%) during today's trading.
Stocks Coverage on Biotech Equities -- Research on Gilead Sciences, ARIAD Pharma, Rexahn Pharma, and Geron
PR Newswire - Fri May 30, 6:10AM CDT
On Thursday, May 29, 2014, the NASDAQ Composite ended at 4,247.95, up 0.54%, the Dow Jones Industrial Average finished the day 0.39% higher at 16,698.74, and the S&P 500 closed at 1,920.03, up 0.54%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 688.45, up 0.76%, and the index has advanced 2.45% in the last one month. Investor-Edge has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN) and Geron Corp. (NASDAQ: GERN). Free technical research on GILD, ARIA, RNN and GERN can be downloaded upon signing up at:
Three biotechs stocks with positive institutional transactions, good price to cash ratios and "buy" recommendations from street analysts
ACCESSWIRE - Thu May 22, 7:09AM CDT
LOS ANGELES / ACCESSWIRE / May 22, 2014 / The names of big-board biotechnology listed firms IsoRay, Inc. (NYSE MKT: ISR), CEL-SCI Corporation (NYSE MKT: CVM), and Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), came up after we set out to find low price biotech stocks with market caps in the $50m to $300m range which, based on a fixed set of fundamental and technical criteria, might be hinting at bullish investment trade sentiments.
Rexahn Pharmaceuticals to Present Data on RX-3117 and RX-21101 at the 2014 American Association for Clinical Research Annual Meeting
Business Wire - Wed Apr 02, 8:00AM CDT
--RX-21101, a nano-polymer targeted form of docetaxel, demonstrates increased efficacy and reduced toxicity
Active Equities Updates -- Research on Valero Energy, UTi Worldwide, SLM Corp., and Rexahn Pharma
PR Newswire - Tue Apr 01, 8:00AM CDT
The trading session on Monday, March 31, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,457.66, up 0.82% and the NASDAQ Composite closed at 4,198.99, up 1.04%. The S&P 500 finished the session 0.79% higher at 1,872.34. The gains were broad based as nine out of ten sectors finished higher. During the session, gains in the Health Care, Materials, and Utilities sectors positively impacted the broader market. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include Valero Energy Corp. (NYSE: VLO), UTi Worldwide Inc. (NASDAQ: UTIW), SLM Corp. (NASDAQ: SLM) and Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN). Free technical research on VLO, UTIW, SLM and RNN can be downloaded upon signing up at:
Rexahn Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results and Recent Highlights
Business Wire - Mon Mar 24, 7:00AM CDT
--Archexin(R) Phase IIa clinical trial initiated in metastatic renal cell carcinoma
3 Stocks Under $10 Making Big Moves
at The Street - Wed Mar 19, 5:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Rexahn Pharmaceuticals to Present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum in New York
Business Wire - Mon Mar 17, 7:00AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Vikas Sharma, Ph.D., the Company's Director, Business Development, will present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum in New York on Wednesday, March 19, 2014. Dr. Sharma will also serve on an expert panel titled "Strategies for small molecules and biologicals drug development." The conference will take place at New York Academy of Sciences, located at 250 Greenwich St, New York, NY.
This Week in Biotech: NW Bio Soars While Geron Goes Geronimo
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 15, 2:15PM CDT
With the SPDR S&P Biotech Index up 59% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Phase I Data on Rexahn's Supinoxin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 4:30PM CDT
Initial data from phase I study on Rexahn's Supinoxin showed that the drug was well tolerated in cancer patients with solid tumors.
Why Rexahn Pharmaceuticals Inc. Jumped Higher
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 11, 1:58PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Rexahn Pharmaceuticals , a clinical-stage...
Rexahn Pharmaceuticals Up 11.1%, Shares Break Through Resistance (RNN)
Comtex SmarTrend(R) - Tue Mar 11, 11:41AM CDT
Rexahn Pharmaceuticals (AMEX:RNN) is one of today's best performing low-priced stocks, up 11.1% to $1.38 on 1.0x average daily volume. Thus far today, Rexahn Pharmaceuticals has traded 11.0 million shares, vs. average volume of 10.6 million shares per day. The stock has outperformed the Dow (10.7% to the Dow's -0.3%) and outperformed the S&P 500 (10.7% to the S&P's -0.3%) during today's trading.
Investor-Edge.com Pre-market Biotech Picks: Rexahn Pharma, Amgen, Galena Biopharma, and MannKind
PR Newswire - Tue Mar 11, 10:32AM CDT
On Monday, March 10, 2014, the NASDAQ Composite ended at 4,334.45, down 0.04%, the Dow Jones Industrial Average fell 0.21% to 16,418.68, and the S&P 500 closed at 1,877.17, down 0.05%. The losses were broad based as six out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 689.78, up 0.39%, and has gained 4.92% in the last one month. Investor-Edge.com has initiated coverage on the following equities: Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN), Amgen Inc. (NASDAQ: AMGN), Galena Biopharma Inc. (NASDAQ: GALE), and MannKind Corporation (NASDAQ: MNKD). Free research on these four companies can be accessed at:
Rexahn Announces Initial Results from Phase I Trial of Supinoxin(TM) (RX-5902) for Solid Cancer Tumors
Business Wire - Tue Mar 11, 7:00AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company announced today initial data for the Phase I dose-escalation clinical trial of Supinoxin(TM) (RX-5902) initiated in August 2013. This trial was designed to study safety and efficacy in patients with solid cancer tumors.
Biotech Stock Mailbag: Exact Sciences, Rexahn, Advaxis, Peregrine
at The Street - Fri Mar 07, 9:49AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Rexahn Pharmaceuticals to Present at the 26th Annual ROTH Conference
Business Wire - Tue Mar 04, 7:00AM CST
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Peter Suzdak, PhD, the Company's Chief Executive Officer and Ted Jeong, Chief Financial Officer, will present at the 26th Annual ROTH Conference on Tuesday, March 11, 2014 at 2:00 p.m. Pacific Time. The conference takes place at The Ritz-Carlton in Dana Point, California. A webcast of the presentation will be available on www.rexahn.com.
Rexahn Pharmaceuticals Appoints Mark Carthy to Board of Directors
Business Wire - Mon Mar 03, 7:00AM CST
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company, announced today the appointment of Mark P. Carthy to the company's Board of Directors.
